First-in-human study of an optimized, potential kit-type, SSTR antagonist ⁶⁸Ga-DATA^5m-LM4 in patients with metastatic neuroendocrine tumors.

ABSTRACT: Radiolabeled somatostatin receptor (SSTR) agonists ⁶⁸Ga-DOTA-TATE and ⁶⁸Ga-DOTA-TOC are widely applied for imaging of patients with neuroendocrine tumors (NETs). Preclinical and preliminary clinical evidence has indicated that SSTR antagonists perform better for NET imaging. In this study, we assessed the feasibility of using a new hybrid chelator DATA^5m ((6-pentanoic acid)-6-(amino)methyl-1,4-diazepinetriacetate))-conjugated kit-type SSTR antagonist ⁶⁸Ga-DATA^5m-LM4 for PET and evaluated the safety, biodistribution, and preliminary diagnostic efficacy of ⁶⁸Ga-DATA^5m-LM4 in patients with metastatic NETs. Methods: The DATA^5m-conjugated form of LM4, was labeled with ⁶⁸Ga. A total of 27 pa

SUBMITTER: Zhang J 

PROVIDER: S-EPMC11840726 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature